| Document Date: 2014-08-08 16:37:50
Open Document File Size: 190,34 KBShare Result on Facebook
City MK / / Company Merck / Idenix Pharmaceuticals / / Country Japan / United States / / Event M&A / FDA Phase / / Facility Merck Pipeline / / IndustryTerm manufacturing difficulties / pharmaceutical industry regulation / / MedicalCondition HPV-Related Cancers HPV / Insomnia / New Molecular Entities Under Review Fertility New Molecular Entities Under Review New Molecular Entities Approvals2 Melanoma Allergy / Cancer / HIV / Herpes Zoster / Neuromuscular Blockade Reversal Allergy / V419 Psoriasis / Thrombosis ZONTIVITY / difficile Infection / Next Generation Ring Atherosclerosis / HIV Alzheimer’s Disease / Diabetes Mellitus / Next Generation Ring Allergy / V212 Osteoporosis / Non-Small Cell Lung Cancer / hypersensitivity / / MedicalTreatment Contraception / / Organization European Medicines Agency / FDA / Committee for Medicinal Products for Human Use / European Union / Securities and Exchange Commission / / Position general economic factors / Private / / Product NOXAFIL / lamivudine / MK-7622 / MK-5348 / NOXAFIL® / / URL www.sec.gov / /
SocialTag |
Merck Pipeline July 31, 2014 Merck Pipeline as of July 31, 20141 Phase 2